2025-11-23 - Analysis Report
Okay, here's an analysis of Teladoc Health Inc. (TDOC) based on the provided information.

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** TDOC
*   **Company:** Teladoc Health Inc. (Provides virtual healthcare services.)

**Key Numbers:**

*   **TDOC Cumulative Return:** -65.99%
*   **VOO Cumulative Return:** 96.29%
*   **Spread:**
    *   Max: 312.1
    *   Min: -167.0
    *   Current: -166.3
    *   Relative Spread: 0.1

**Analysis of Alpha, Beta:**

The following table shows Alpha, Beta, CAGR and MDD.

| Year       | CAGR     | MDD      | Alpha   | Beta  | Cap(B) |
|------------|----------|----------|---------|-------|--------|
| 2015-2017  | 77.0%    | 70.4%    | 51.0%   | -0.0  | 6.2    |
| 2016-2018  | 101.0%   | 69.4%    | 86.0%   | -0.0  | 8.8    |
| 2017-2019  | 141.0%   | 73.8%    | 118.0%  | 0.4   | 14.9   |
| 2018-2020  | 105.0%   | 80.9%    | 81.0%   | 0.3   | 35.5   |
| 2019-2021  | -78.0%   | 80.9%    | -125.0% | 0.3   | 16.3   |
| 2020-2022  | -252.0%  | 85.9%    | -251.0% | -0.9  | 4.2    |
| 2021-2023  | -315.0%  | 85.9%    | -316.0% | -1.8  | 3.8    |
| 2022-2024  | -93.0%   | 85.9%    | -113.0% | -2.0  | 1.6    |
| 2023-2025  | -37.0%   | 81.6%    | -96.0%  | -0.8  | 1.2    |

**Analysis:**

*   TDOC has significantly underperformed the S&P 500. The cumulative return difference is quite large (-166.3).
*   The relative spread of 0.1 suggests that the current underperformance is near the lowest it has been historically within the data provided.
*   The Alpha,Beta analysis shows a significant deterioration in performance in recent years.
    *   Early periods (2015-2020) showed high CAGR and positive Alpha, indicating strong outperformance.
    *   More recent periods (2019-2025) show substantial negative CAGR and negative Alpha, demonstrating significant underperformance.
    *   Beta has fluctuated, suggesting varying levels of correlation with the market. However, in recent years, Beta has become more negative, indicating an inverse relationship with the market (TDOC tends to move in the opposite direction of the market).

**2. Recent Stock Price Movement**

**Key Numbers:**

*   **Closing Price:** 6.96
*   **Last Market Data:** price: 6.96, previousClose: 6.76, change: 2.96%
*   **5-Day Moving Average:** 6.904
*   **20-Day Moving Average:** 7.6775
*   **60-Day Moving Average:** 8.0371

**Analysis:**

*   The stock price closed at 6.96, showing a 2.96% increase from the previous close, indicating a positive short-term movement.
*   The 5-day moving average is below the 20-day and 60-day moving averages, suggesting a potential short-term upward trend, but still below the longer-term trends.

**3. Market Risk Indicator and Expected Return**

**Key Numbers:**

*   **MRI:** 0.8 (Medium Investment Recommended)
*   **RSI:** 25.31 (Oversold)
*   **PPO:** -1.1888
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (110 shares - Very Safe - MRI:0.90) (Cash Ratio: 0% on 2025-10-03)
*   **Recent (20-day) Relative Spread Change:** -0.5 (Negative - Short-term decline)
*   **Expected Return:** -10069.8% (Long-term, relative to S&P 500)

**Analysis:**

*   The MRI of 0.8 suggests a medium level of investment risk.
*   An RSI of 25.31 indicates the stock is oversold, potentially signaling a buying opportunity.
*   The negative PPO suggests a downtrend.
*   The Hybrid Signal recommends buying with all available cash, viewing it as "Very Safe."
*   The 20-day relative spread change indicates a recent short-term decline.
*   The significantly negative expected return (-10069.8%) suggests that, based on the model, the stock is projected to dramatically underperform the S&P 500 over the long term if bought at the current price.
*   The increase of price(2.96%) from previous close may be a sign of short covering or a minor rebound after a downtrend, but further monitoring is needed to confirm a trend reversal.

**4. Recent News & Significant Events**

*   **Acquisition Strategy:** Articles discuss whether Teladoc's acquisition strategy will boost growth.
*   **Stock Performance:** Some articles note the stock is falling.
*   **Competitor Comparison:** One article compares TDOC to LFMD (another telehealth stock).
*   **Virtual Care Strategy:** Articles discuss a potential shift in virtual care strategy with TytoCare collaboration.
*   **Analyst Opinion:** An article discusses whether the stock is a buy after Oracle Investment Management increased its stake.

**Analysis:**

*   The news is mixed. There's discussion about potential growth strategies and investment, but also concerns about falling stock prices and comparisons to competitors.

**4-2. Analyst Opinions**

*   **Consensus:** Hold
*   **Mean Rating:** 2.65 (~Hold)
*   **Opinions:** 21
*   **Target Price:**
    *   Average: 9.26
    *   High: 12.00
    *   Low: 7.00

**Analysis:**

*   Analyst consensus is "Hold," with an average rating of 2.65.
*   The average target price of 9.26 suggests potential upside from the current price of 6.96. However, the low target price of 7.00 is near the current price.

**5. Recent Earnings Analysis**

| 날짜         | EPS   | 매출       |
|--------------|-------|------------|
| 2025-10-30   | -0.28 | 0.63 B$    |
| 2025-07-30   | -0.19 | 0.63 B$    |
| 2025-05-01   | -0.53 | 0.63 B$    |
| 2024-10-31   | -0.19 | 0.64 B$    |
| 2025-10-30   | -0.19 | 0.64 B$    |

**Analysis:**

*   Teladoc has consistently reported negative EPS for the past several quarters.
*   Revenue has been relatively stable around $0.63-0.64 billion.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30   | $0.63B     | 70.12%        |
| 2025-06-30   | $0.63B     | 69.85%        |
| 2025-03-31   | $0.63B     | 68.73%        |
| 2024-12-31   | $0.64B     | 70.50%        |
| 2024-09-30   | $0.64B     | 71.94%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE        |
|--------------|------------|------------|
| 2025-09-30   | $1.39B     | -3.56%     |
| 2025-06-30   | $1.42B     | -2.30%     |
| 2025-03-31   | $1.43B     | -6.52%     |
| 2024-12-31   | $1.49B     | -3.25%     |
| 2024-09-30   | $1.51B     | -2.21%     |

**Analysis:**

*   Revenue has been relatively consistent.
*   Profit margins have been relatively stable.
*   Equity has slightly decreased over the past year.
*   Return on Equity (ROE) has been negative, indicating unprofitability.

**7. Overall Summary**

Teladoc (TDOC) has significantly underperformed the S&P 500. Recent financial performance shows consistent revenue, but negative earnings and ROE. Analyst consensus is "Hold," with a target price that suggests potential upside. Recent news is mixed, with both positive and negative headlines. The stock is currently oversold according to the RSI, and the Hybrid Signal suggests a buying opportunity, but the negative expected return indicates a very bearish long-term outlook relative to the market. The increase of price(2.96%) from previous close may be a sign of short covering or a minor rebound after a downtrend.
